Fibrous Dysplasia of Bone Clinical Trial
Official title:
Epigenetic Regulation of Activity and Severity of Fibrous Dysplasia in Bone: mirDYS Study.
Fibrous dysplasia of bone is a rare congenital but non-hereditary disease caused by a post-zygotic activation mutation of the GNAS gene. Patients with fibrous dysplasia may present pain and bone complications (fractures, deformities..) related to their bone lesions. For undetermined reasons, severity and disease evolution may vary considerably from patient to patient. Epigenetic regulation could then be involved, including micro Ribonucleic Acids (miRs). These small non-coding micro Ribonucleic Acids are involved in the regulation of major steps of cellular processes in different pathologies, in particular in bone diseases. However, micro Ribonucleic Acids have never been studied in fibrous dysplasia. The aim of this study is to identify micro Ribonucleic Acids significantly associated with the severity of fibrous dysplasia.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01791842 -
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
|
Phase 2 | |
| Completed |
NCT00445575 -
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
|
Phase 2/Phase 3 | |
| Completed |
NCT05422833 -
Effectiveness of Medical Management of Fibrous Dysplasia of Bone.
|
||
| Recruiting |
NCT06177327 -
Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome
|
||
| Active, not recruiting |
NCT05509595 -
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
|
Phase 2 |